Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.55 |
| ▸ | RPS6KA2 | Q15349 | 14/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16123265 | 1.00 | MAPKAPK2 (0.55) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL16100908 | 1.00 | MAPKAPK2 (0.55) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL16101081 | 0.87 | RPS6KA3 (0.48) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL16101080 | 0.87 | RPS6KA3 (0.48) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL17371361 | 0.84 | RPS6KA2 (0.53) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL16123221 | 0.82 | MAPKAPK2 (0.59) | MAPKAPK2RPS6KA2 | |
| SCHEMBL17371360 | 0.81 | MAPKAPK2 (0.57) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL17361118 | 0.81 | MAPKAPK2 (0.54) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL16123159 | 0.81 | MAPKAPK2 (0.54) | MAPKAPK2RPS6KA2RPS6KA3 | |
| SCHEMBL17361155 | 0.81 | MAPKAPK2 (0.54) | MAPKAPK2RPS6KA2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885RPS6KA2 11/4885RPS6KA3 75/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885RPS6KA2 11/4885RPS6KA3 75/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885RPS6KA2 11/4885RPS6KA3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.